Alector reports fourth quarter and full year 2024 financial results and provides business update

Topline data from the pivotal infront-3 phase 3 clinical trial of latozinemab in ftd-grn expected by q4 2025 anticipate completing enrollment in the progress-ad phase 2 clinical trial of al101/gsk 4527226 in participants with early alzheimer's disease by mid-2025 applying alector brain carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing gcase $413.4 million in cash, cash equivalents and investments provide runway through 2026 management to host conference call and webcast today at 4:30 p.m. et/1:30 p.m.
ALEC Ratings Summary
ALEC Quant Ranking